448 related articles for article (PubMed ID: 9762669)
1. Time-course analysis of CD25 and HLA-DR expression on lymphocytes in interferon-beta 1b-treated multiple sclerosis patients.
Ferrarini AM; Sivieri S; Buttarello M; Facchinetti A; Perini P; Gallo P
Mult Scler; 1998 Jun; 4(3):174-7. PubMed ID: 9762669
[TBL] [Abstract][Full Text] [Related]
2. Time-course of interleukin-2 receptor expression in interferon beta-treated multiple sclerosis patients.
Ferrarini AM; Sivieri S; Bulian P; Buttarello M; Biasi G; Tavolato B; Gallo P
J Neuroimmunol; 1998 Apr; 84(2):213-7. PubMed ID: 9628465
[TBL] [Abstract][Full Text] [Related]
3. Increased CD80(+) B cells in active multiple sclerosis and reversal by interferon beta-1b therapy.
Genç K; Dona DL; Reder AT
J Clin Invest; 1997 Jun; 99(11):2664-71. PubMed ID: 9169496
[TBL] [Abstract][Full Text] [Related]
4. T-cell interleukin-6 receptor binding in interferon-beta-1b-treated multiple sclerosis patients.
Bongioanni P; Lombardo F; Moscato G; Mosti S; Meucci G
Eur J Neurol; 2000 Nov; 7(6):647-53. PubMed ID: 11136350
[TBL] [Abstract][Full Text] [Related]
5. Further study on the specificity and incidence of neutralizing antibodies to interferon (IFN) in relapsing remitting multiple sclerosis patients treated with IFN beta-1a or IFN beta-1b.
Antonelli G; Simeoni E; Bagnato F; Pozzilli C; Turriziani O; Tesoro R; Di Marco P; Gasperini C; Fieschi C; Dianzani F
J Neurol Sci; 1999 Oct; 168(2):131-6. PubMed ID: 10526196
[TBL] [Abstract][Full Text] [Related]
6. Natural killer cells in relapsing-remitting MS: effect of treatment with interferon beta-1B.
Kastrukoff LF; Morgan NG; Zecchini D; White R; Petkau AJ; Satoh J; Paty DW
Neurology; 1999 Jan; 52(2):351-9. PubMed ID: 9932956
[TBL] [Abstract][Full Text] [Related]
7. Interferon beta-1b reduces interferon gamma-induced antigen-presenting capacity of human glial and B cells.
Jiang H; Milo R; Swoveland P; Johnson KP; Panitch H; Dhib-Jalbut S
J Neuroimmunol; 1995 Aug; 61(1):17-25. PubMed ID: 7560008
[TBL] [Abstract][Full Text] [Related]
8. Autoantibodies in multiple sclerosis patients before and during IFN-beta 1b treatment: are they correlated with the occurrence of autoimmune diseases?
Verdun E; Isoardo G; Oggero A; Ferrero B; Ghezzi A; Montanari E; Zaffaroni M; Durelli L;
J Interferon Cytokine Res; 2002 Feb; 22(2):245-55. PubMed ID: 11911808
[TBL] [Abstract][Full Text] [Related]
9. T-cell interferon gamma receptor binding in interferon beta-1b-treated patients with multiple sclerosis.
Bongioanni P; Lombardo F; Moscato G; Mosti S; Meucci G
Arch Neurol; 1999 Feb; 56(2):217-22. PubMed ID: 10025427
[TBL] [Abstract][Full Text] [Related]
10. Lymphocyte subpopulations, oxidative burst and apoptosis in peripheral blood cells of patients with multiple sclerosis-effect of interferon-beta.
Mix E; Stefan K; Höppner J; Klauer T; Zettl UK; Strauss U; Meyer-Rienecker HJ; Rolfs A
Autoimmunity; 2003 Aug; 36(5):291-305. PubMed ID: 14567559
[TBL] [Abstract][Full Text] [Related]
11. Circulating CD4+CD25+ T regulatory cells are not altered in multiple sclerosis and unaffected by disease-modulating drugs.
Putheti P; Pettersson A; Soderstrom M; Link H; Huang YM
J Clin Immunol; 2004 Mar; 24(2):155-61. PubMed ID: 15024182
[TBL] [Abstract][Full Text] [Related]
12. Immunomodulatory effects of interferon-beta-1b in patients with multiple sclerosis.
Ossege LM; Sindern E; Patzold T; Malin JP
Int Immunopharmacol; 2001 Jun; 1(6):1085-100. PubMed ID: 11407304
[TBL] [Abstract][Full Text] [Related]
13. Multiple sclerosis: expression of CD1a and production of IL-12p70 and IFN-gamma by blood mononuclear cells in patients on combination therapy with IFN-beta and glatiramer acetate compared to monotherapy with IFN-beta.
Hussien Y; Sanna A; Söderström M; Link H; Huang YM
Mult Scler; 2004 Feb; 10(1):16-25. PubMed ID: 14760948
[TBL] [Abstract][Full Text] [Related]
14. Effect of immunomodulatory treatment of multiple sclerosis on lymphocyte surface immunomarkers.
Michałowska-Wender G; Losy J; Wender M; Januszkiewicz-Lewandowska D; Nowak J
Pol J Pharmacol; 2003; 55(5):877-80. PubMed ID: 14704481
[TBL] [Abstract][Full Text] [Related]
15. Statins as immunomodulators: comparison with interferon-beta 1b in MS.
Neuhaus O; Strasser-Fuchs S; Fazekas F; Kieseier BC; Niederwieser G; Hartung HP; Archelos JJ
Neurology; 2002 Oct; 59(7):990-7. PubMed ID: 12370451
[TBL] [Abstract][Full Text] [Related]
16. [Current status of interferon beta-1b in multiple sclerosis therapy].
Hartung HP
Med Klin (Munich); 2001 Sep; 96 Suppl 1():11-6. PubMed ID: 11603110
[TBL] [Abstract][Full Text] [Related]
17. Interferon beta for multiple sclerosis.
Connelly JF
Ann Pharmacother; 1994 May; 28(5):610-6. PubMed ID: 8069001
[TBL] [Abstract][Full Text] [Related]
18. Interferon-beta enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis.
Schreiner B; Mitsdoerffer M; Kieseier BC; Chen L; Hartung HP; Weller M; Wiendl H
J Neuroimmunol; 2004 Oct; 155(1-2):172-82. PubMed ID: 15342209
[TBL] [Abstract][Full Text] [Related]
19. Effects of beta-IFN-1b treatment in MS patients on adhesion between PBMNCs, HUVECs and MS-HBECs: an in vivo and in vitro study.
Corsini E; Gelati M; Dufour A; Massa G; Nespolo A; Ciusani E; Milanese C; La Mantia L; Salmaggi A
J Neuroimmunol; 1997 Oct; 79(1):76-83. PubMed ID: 9357450
[TBL] [Abstract][Full Text] [Related]
20. Neutralizing and binding anti-interferon-beta (IFN-beta) antibodies. A comparison between IFN-beta-1a and IFN-beta-1b treatment in multiple sclerosis.
Kivisäkk P; Alm GV; Fredrikson S; Link H
Eur J Neurol; 2000 Jan; 7(1):27-34. PubMed ID: 10809912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
